Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ibrutinib Combinations in Advanced GI/GU Tumors
NCT02599324Phase 2Completed
- Sponsor
- Pharmacyclics
- Start
- Dec 2015
- Primary completion
- Aug 2021
- Modality
- Small Molecules
- Countries
- 4
01
Overview
A Phase 2 trial of ibrutinib in renal cell carcinoma (RCC), urothelial carcinoma (UC), gastric adenocarcinoma, colorectal adenocarcinoma, sponsored by Pharmacyclics. Started Dec 2015; status: completed.
02
Drugs
ibrutinib
03
Conditions
renal cell carcinoma (RCC)urothelial carcinoma (UC)gastric adenocarcinomacolorectal adenocarcinoma
Beyond the preview
Go deeper on NCT02599324.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02599324.